Saw Palmetto Extract in Benign Prostatic Hyperplasia

• Status: Completed
• Trial end date: 2002-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to test whether an extract of the saw palmetto plant is effective for relieving symptoms of Benign Prostatic Hyperplasia (BPH).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Collaborator: National Center for Complementary and Integrative Health (NCCIH)
• Treatments: Permixon; Saw palmetto extract

Criteria

Eligibility Criteria:

• Participants must be men, aged 50 years or older with moderate-to-severe BPH.

• Participants must not have a history of prostate cancer, prior surgery on the prostate, kidney failure, or taking furosemide (Lasix), warfarin (Coumadin), or hormone medications. Individuals taking medicine for their BPH must stop them for one month (prazosin, terazosin (Hytrin), doxazosin (Cardura), tamsulosin (Flomax)) or six months (saw palmetto, finasteride (Proscar or Rogaine)) prior to entering the study.